This study will access the GI complaints on patients reported outcomes and to determine the improvement in quality of life in patients.

Inclusion Criteria:

• Patient received kidney transplant at least 1 month prior to study with MMF as a part of the treatment for at least 2 weeks.
• Eligible to convert to myfortic because of GI complaints or not currently experiencing GI complaints and stable on current immunosuppressive regimen.
• At least 18 years of age;
• Willing to provide written informed consent; and
• Able to meet all study requirements including completing paper questionnaires and completing two study visits.

Exclusion Criteria:

• GI symptoms assumed or known not be caused by MPA therapy and have recent acute rejection at least 1 week prior to the study.
• Breast-feeding or pregnant woman.
• Patients with psychiatric illness.
• Underlying acute medical intervention or hospitalization
• Receiving investigational drug within 30days prior to study.

Kidney transplanted Patients currently on MMF who have GI symptoms and will be converted to EC-MPS treatment and patients currently on MMF without GI symptoms who will continue with MMF therapy.